Prasol Chemicals IPO Review: 84% OFS, 48x FY26

Company: Prasol Chemicals Ltd · Navi Mumbai · acetone- and phosphorus-based speciality chemicals, exports to 60+ countries · mainboard IPO, NSE and BSE

Key takeaways

• The book is ₹500 crore: ₹80 crore fresh (₹60 crore to repay debt), ₹420 crore OFS — 84% of the issue.
• Revenue from operations rose ₹876.56 crore → ₹1,012.49 crore → ₹1,232.59 crore; PAT ₹18.13 → ₹43.57 → ₹83.12 crore. EBITDA margin 6.91% → 11.30%.
• Operating cash was ₹115.61 crore in FY24 and only ₹49.47 crore in FY26 — profit grew faster than cash.
• At ₹676, post-issue mcap is about ₹4,001 crore, or 48.1x FY26 and 91.9x FY25.
• Named peers on 3 Sep 2026: Excel Industries 18.2x, Vinati Organics 27.3x, Aarti Industries 34.8x. An unofficial GMP of ₹55 (~8%) has been quoted — unofficial, unregulated, often wrong.

The deal in one paragraph

Prasol is a 1992 speciality-chemicals manufacturer with 150-plus acetone and phosphorus products and an export book. Coverage calls it India’s only isophorone maker. The three-year margin expansion is in the abridged prospectus, not in a broker’s adjective. The offer still asks 48 times that year, after a year when cash from operations was less than half of FY24, and 84% of the ₹500 crore is a sale by existing holders. Niche is not a multiple. Our verdict is avoid at ₹676; the reasoning is below.

Data

Issue structure

Item	Figure	Units
Total issue	500	₹ cr
Fresh issue	80	₹ cr
OFS	420	₹ cr
Price band	643–676	₹ / share
Lot	22	shares (₹14,872 at the cap)
Pre / post shares	5.80 / 5.92	cr
Debt repayment from fresh	60	₹ cr
Listing (tentative)	16 Sep 2026	NSE + BSE

Source: Paytm Money; CNBC-TV18. Tickers named above are listed peers used for comparison, not recommendations.

₹80 crore in, ₹420 crore out; the largest single use of the fresh money is debt repayment.

Units: ₹ cr · Source: Paytm Money; CNBC-TV18

Financials (restated, ₹ cr)

	FY24	FY25	FY26
Revenue from operations	876.56	1,012.49	1,232.59
Operating EBITDA	60.53	87.77	139.32
EBITDA margin	6.91%	8.67%	11.30%
PAT	18.13	43.57	83.12
PAT margin	2.07%	4.30%	6.74%
Operating cash flow	115.61	22.26	49.47
Borrowings	82.07	101.05	110.06
EPS (₹)	3.13	7.51	14.33
NAV (₹)	56.18	63.35	77.33

Units: ₹ crore except per-share figures and margins. Source: SEBI abridged prospectus. IPO Watch flags commitments of ₹99.11 crore and contingent liability ₹10.02 crore as of 31 Mar 2026.

PAT margin moved from 2.07% to 6.74%; the bars show how thin the profit line still is against revenue.

Units: ₹ crore · Source: SEBI abridged prospectus

FY26 operating cash (₹49.47 crore) is less than half of FY24 and below FY26 PAT.

Units: ₹ crore · Source: SEBI abridged prospectus

Valuation at the upper band

Metric	At ₹676
Post-issue mcap (derived)	~₹4,001 cr
P/E FY26	48.1x
P/E FY25	91.9x
P/B on NAV ₹77.33	8.74x
Aarti Industries P/E (3 Sep)	34.8x
Vinati Organics P/E	27.3x
Atul P/E	24.0x
Excel Industries P/E	18.2x

Units: rupees crore and times. Source: IPO Watch peer table dated 3 Sep 2026; mcap derived from Paytm Money post-issue share count × ₹676.

Every named peer trades below the IPO multiple; the FY25 bar shows what the price looks like on the year before margins doubled.

Units: times (x) · Source: IPO Watch, 3 Sep 2026

Subscription and unofficial GMP

CNBC-TV18 quoted an unofficial GMP of ₹55 versus ₹676 on 8 Sep (~8%). Early Day-1 subscription prints were around 0.14x. Grey-market premiums are informal and often wrong; I do not treat them as a listing forecast.

Risks

• 84% OFS. ₹80 crore in, ₹420 crore out.
• 48x on the year margins doubled; 92x on the year before.
• Cash lagged profit. FY26 OCF is below FY24.
• Plant-shutdown risk on a manufacturing book (broker notes via CNBC-TV18).
• Acetone / phosphorus input cycle.
• Commitments near ₹99 crore against an ₹80 crore fresh issue.

AlphaResearch verdict

Avoid at ₹676. Clears 1 of 5 checks (business). Numbers are partial. Price and OFS fail.

Avoid at ₹676Clears 1 of 5

1. ✓Business · Clears150-plus acetone and phosphorus products; exports to 60+ countries; documented margin expansion 6.91% → 11.30%.
2. ~Numbers · PartialPAT ₹18.13 → ₹83.12 crore, but operating cash fell from ₹115.61 crore (FY24) to ₹49.47 crore (FY26).
3. ✗Price · Fails48.1x FY26 vs Aarti 34.8x, Vinati 27.3x, Atul 24.0x, Excel 18.2x; 91.9x on FY25.
4. ✗Structure · Fails₹420 crore of ₹500 crore (84%) is an OFS; ₹60 crore of the ₹80 crore fresh goes to debt repayment.
5. ✗Red flags · FailsCommitments ₹99.11 crore against an ₹80 crore fresh issue; input-cycle and plant-shutdown risk.

Why: the product niche and the three-year margin expansion are real and documented in the abridged prospectus. The offer still asks 48 times that year after operating cash fell to less than half of FY24, and 84% of the ₹500 crore is existing holders selling. Niche is not a multiple, and a shrinking cash conversion in the year you are being asked to pay up is the wrong direction.

What flips this verdict: two quarters holding EBITDA margin at or above 11% with operating cash at least matching PAT moves us to Neutral. A live price nearer the Vinati / Aarti multiples on FY26 earns a full re-read.

Dates: allotment 11 Sep; listing tentatively 16 Sep 2026.

A companion video is planned; numbers will come only from this article and docs/ipo_analysis/prasol_chemicals.md.

Disclaimer

AlphaResearch is not a SEBI-registered investment adviser or research analyst. The verdict in this article is AlphaResearch’s independent opinion, formed from publicly available information as of the date shown; it is not personalised investment advice and does not consider your financial situation, goals or risk tolerance. Figures are taken from the sources listed below and may contain errors; verify them in the original filings. Investing in securities involves risk, including loss of principal. Consult a SEBI-registered adviser before acting on anything here.

Position disclosure: none. AARTIIND, ATUL and VINATIORGA appear only as listed-peer comparables.